Cocrystal Pharma appoints Carol Brosgart, MD to board of directors

Cocrystal Pharma, Inc.

Carol Brosgart, MD appointed to board effective August 12, 2026.
Brings decades of antiviral therapy and epidemiology experience; contributed to FDA-approved therapies.
Previously held roles at Gilead Sciences and Tobira; served on multiple biotech boards.
Will guide clinical development of CDI-988 for norovirus and broader antiviral pipeline.
Currently on boards of Galmed, Eradivir, and Merlin Biotech.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.